Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Genetics and Epidemiology
  • View Item
  • Home
  • ICR Divisions
  • Genetics and Epidemiology
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.

Thumbnail
View/Open
Published version (867.9Kb)
Publication Date
2019-02
ICR Author
Eeles, Rosalind
Dearnaley, David
Kumar, Pardeep
van As, Nick
Kote-Jarai, Zsofia
Author
Bancroft, EK
Saya, S
Page, EC
Myhill, K
Thomas, S
Pope, J
Chamberlain, A
Hart, R
Glover, W
Cook, J
Rosario, DJ
Helfand, BT
Hutten Selkirk, C
Davidson, R
Longmuir, M
Eccles, DM
Gadea, N
Brewer, C
Barwell, J
Salinas, M
Greenhalgh, L
Tischkowitz, M
Henderson, A
Evans, DG
Buys, SS
IMPACT Study Steering Committee
IMPACT Collaborators
Eeles, RA
Aaronson, NK
Type
Journal Article
Metadata
Show full item record
Abstract
<h4>Objectives</h4>To report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi-national investigation of targeted prostate cancer (PCa) screening among men with a known pathogenic germline mutation in the BRCA1 or BRCA2 genes.<h4>Particpants and methods</h4>Men enrolled in the IMPACT study were invited to complete a questionnaire at collaborating sites prior to each annual screening visit. The questionnaire included sociodemographic characteristics and the following measures: the Hospital Anxiety and Depression Scale (HADS), Impact of Event Scale (IES), 36-item short-form health survey (SF-36), Memorial Anxiety Scale for Prostate Cancer, Cancer Worry Scale-Revised, risk perception and knowledge. The results of the baseline questionnaire are presented.<h4>Results</h4>A total of 432 men completed questionnaires: 98 and 160 had mutations in BRCA1 and BRCA2 genes, respectively, and 174 were controls (familial mutation negative). Participants' perception of PCa risk was influenced by genetic status. Knowledge levels were high and unrelated to genetic status. Mean scores for the HADS and SF-36 were within reported general population norms and mean IES scores were within normal range. IES mean intrusion and avoidance scores were significantly higher in BRCA1/BRCA2 carriers than in controls and were higher in men with increased PCa risk perception. At the multivariate level, risk perception contributed more significantly to variance in IES scores than genetic status.<h4>Conclusion</h4>This is the first study to report the psychosocial profile of men with BRCA1/BRCA2 mutations undergoing PCa screening. No clinically concerning levels of general or cancer-specific distress or poor quality of life were detected in the cohort as a whole. A small subset of participants reported higher levels of distress, suggesting the need for healthcare professionals offering PCa screening to identify these risk factors and offer additional information and support to men seeking PCa screening.
URL
https://repository.icr.ac.uk/handle/internal/1891
Collections
  • Genetics and Epidemiology
  • Radiotherapy and Imaging
  • Closed Research Teams
Licenseref URL
http://www.rioxx.net/licenses/under-embargo-all-rights-reserved
Version of record
10.1111/bju.14412
Subject
IMPACT Study Steering Committee
IMPACT Collaborators
Humans
Prostatic Neoplasms
Risk Factors
Case-Control Studies
Longitudinal Studies
Health Knowledge, Attitudes, Practice
Depression
Anxiety
Perception
Psychiatric Status Rating Scales
Mutation
Genes, BRCA1
Genes, BRCA2
Quality of Life
Adult
Middle Aged
Male
Early Detection of Cancer
Surveys and Questionnaires
Research team
Clinical Academic Radiotherapy (Dearnaley)
Oncogenetics
Stereotactic and Precision Body Radiotherapy
Language
eng
Date accepted
2018-05-21
License start date
2019-02
Citation
BJU international, 2019, 123 (2), pp. 284 - 292

Related items

Showing items related by title, author, creator and subject.

  • Thumbnail

    Impact of genetic modulation of SULT1A enzymes on DNA adduct formation by aristolochic acids and 3‑nitrobenzanthrone 

    Mirza, A; Arlt, VM; Meinl, W; Florian, S; Nagy, E; Barta, F; Thomann, M; Mrizova, I; Krais, AM; Liu, M; Richards, M; Kopka, K; Phillips, DH; Glatt, H; Stiborova, M; Schmeiser, HH
  • Thumbnail

    Prognostic Impact of Fascin-1 (FSCN1) in Epithelial Ovarian Cancer 

    Gevensleben, Heidrun (2013-02)
    Background: Fascin-1 (FSCN1) plays an important role in cancer development and is associated with invasion and metastasis. Therefore, we explored the expression and localization of FSCN1 in epithelial ovarian cancer (EOC). ...
  • Thumbnail

    Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial 

    Moynihan, Clare (2015-07)
    Purpose The NCIC CTG PR3/MRC PR07 randomized phase III trial compared androgen-deprivation therapy (ADT) alone versus ADT with radiotherapy (RT) for patients with locally advanced prostate cancer. This article reports the ...

Browse

All of ICR repositoryICR DivisionsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.